JGXZ treatment significantly increased the SOD and GSH-Px activities and decreased the MDA level in the liver of NAFLD rats (p < 0.01 and p < 0.05, Figure 3(a)). The gene discussed is SOD1; the disease is metabolic dysfunction-associated steatotic liver disease.